Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.

dc.contributor.author

Jenks, Jeffrey D

dc.contributor.author

Salzer, Helmut Jf

dc.contributor.author

Prattes, Juergen

dc.contributor.author

Krause, Robert

dc.contributor.author

Buchheidt, Dieter

dc.contributor.author

Hoenigl, Martin

dc.date.accessioned

2023-08-01T17:59:23Z

dc.date.available

2023-08-01T17:59:23Z

dc.date.issued

2018-01

dc.date.updated

2023-08-01T17:59:22Z

dc.description.abstract

In recent decades, important advances have been made in the diagnosis and treatment of invasive aspergillosis (IA) and mucormycosis. One of these advances has been the introduction of isavuconazole, a second-generation broad spectrum triazole with a favorable pharmacokinetic and safety profile and few drug-drug interactions. Phase III trials in patients with IA and mucormycosis demonstrated that isavuconazole has similar efficacy to voriconazole for the treatment of IA (SECURE trial) and liposomal amphotericin B for the treatment of mucormycosis (VITAL trial with subsequent case-control analysis) and a favorable safety profile with significantly fewer ocular, hepatobiliary, and skin and soft tissue adverse events compared to voriconazole. As a result, recent IA guidelines recommend isavuconazole (together with voriconazole) as gold standard treatment for IA in patients with underlying hematological malignancies. In contrast to liposomal amphotericin B, isavuconazole can be safely administered in patients with reduced renal function and is frequently used for the treatment of mucormycosis in patients with reduced renal function. Updated guidelines on mucormycosis are needed to reflect the current evidence and give guidance on the use of isavuconazole for mucormycosis. Studies are needed to evaluate the role of isavuconazole for 1) anti-mold prophylaxis in high-risk patients, 2) salvage treatment for IA and mucormycosis, and 3) treatment for other mold infections such as Scedosporium apiospermum.

dc.identifier

dddt-12-1033

dc.identifier.issn

1177-8881

dc.identifier.issn

1177-8881

dc.identifier.uri

https://hdl.handle.net/10161/28630

dc.language

eng

dc.publisher

Informa UK Limited

dc.relation.ispartof

Drug design, development and therapy

dc.relation.isversionof

10.2147/dddt.s145545

dc.subject

Animals

dc.subject

Humans

dc.subject

Aspergillosis

dc.subject

Mucormycosis

dc.subject

Nitriles

dc.subject

Triazoles

dc.subject

Pyridines

dc.subject

Antifungal Agents

dc.subject

Drug Design

dc.title

Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.

dc.type

Journal article

duke.contributor.orcid

Jenks, Jeffrey D|0000-0001-6632-9587

pubs.begin-page

1033

pubs.end-page

1044

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, Infectious Diseases

pubs.publication-status

Published

pubs.volume

12

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
DDDT_Jenks_2018.pdf
Size:
596.24 KB
Format:
Adobe Portable Document Format